Puridify, a UK-based developer of a nanofiber-based platform purification technology for the biopharmaceutical industry that is based on research at University College London (UCL), was acquired by healthcare company GE Healthcare yesterday. Financial terms of the transaction have not been disclosed. Puridify has developed technology, dubbed FibroSelect, that improves the efficiency of purification in biopharmaceutical production. The technology is based on research at UCL’s Department of Biochemical Engineering. Following the acquisition, GE Healthcare will invest in Puridify to commercialise the technology and integrate it with its own purification products. The spinout’s 17 staff will move to GE Healthcare Life Sciences’ BioProcess business and remain at their current location. The spinout previously closed a $3.4m series A round in 2015 backed by Touchstone Innovations, the commercialisation firm spun out of Imperial College London, UCL Business, the tech transfer arm of UCL, and SR One, the corporate venturing arm of pharmaceutical firm GlaxoSmithKline. In 2014, Touchstone and SR One co-led a $1.4m seed round that also included UCL Business. Oliver Hardick, chief executive of Puridify, said: “Puridify has spent the last three years developing the industrial FibroSelect technology in close collaboration with leading biomanufacturers with promising results. “We are excited to take this next step as part of GE Healthcare, with the full support and experience associated with one of the industry leaders in this field. “This deal gives full recognition to the Puridify development team and to the strong potential of the FibroSelect technology platform.”
Puridify clears GE Healthcare acquisition
Nov 29, 2017 •
LEADERSHIP SOCIETY
Informing, connecting, and transforming the global corporate venture capital ecosystem.The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Halo has researchers on speed dial for corporates
Halo has researchers on speed dial for corporates
How does a corporate find the right university researcher or startup when it's trying to solve a critical problem? Halo has the answer.
How Basel supercharged its spinout rate
How Basel supercharged its spinout rate
Basel has quietly built a life sciences ecosystem that’s becoming hard to ignore.
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
From a chest-worn device to help with Parkinson's symptoms to stress measuring socks — here are the spinouts providing support for senior citizens.
Events
Webinar: Innovate to heal - What does the hospital of the future look like?
Apr 10, 2024
Online
Online
Events
GCV Institute: Landing the Value of Corporate Venturing
May 6 -
May 9, 2024
Online
May 9, 2024
Online
Events
GCV Institute: CVC Investment Programs
May 21 -
May 22, 2024
Online
May 22, 2024
Online
Events
GCV Symposium 2024
Jun 24 -
Jun 26, 2024
London (UK)
Jun 26, 2024
London (UK)
Events
Corporate Venture in Brasil 2024 – International Delegation to Brazil
Oct 28 -
Oct 30, 2024
São Paulo (Brazil)
Oct 30, 2024
São Paulo (Brazil)
Top News
test reg